Literature DB >> 1928525

Bleach programs for preventing AIDS among i.v. drug users: modeling the impact of HIV prevalence.

J E Siegel1, M C Weinstein, H V Fineberg.   

Abstract

BACKGROUND: The growing importance of drug use as a mode of HIV transmission has led to increased attention to AIDS prevention among intravenous drug users (IVDUs). This analysis examines the effectiveness of bleach distribution, a program to prevent HIV transmission via shared needles.
METHODS: We used a Markov model to assess the role of the initial HIV prevalence among drug users in determining the effectiveness of bleach programs. The model incorporates survey data on risk behaviors and published information describing HIV incubation and mortality. It predicts life expectancy for cohorts of IVDUs with and without a bleach program to estimate program effectiveness.
RESULTS: We found that bleach programs can produce the greatest life-year savings in areas of low HIV prevalence. In the lowest prevalence scenario (0.02 initial prevalence), initiation of the program resulted in a projected savings of 2.3 life years per HIV-negative drug user, compared with 1.7 and 1.3 years under medium (0.25) and high (0.60) prevalence, respectively.
CONCLUSIONS: While bleach programs are beneficial in all groups of IVDUs, these results highlight the advantages of introducing bleach programs early, when prevalence is still comparatively low in a drug-user population.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1928525      PMCID: PMC1405310          DOI: 10.2105/ajph.81.10.1273

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  21 in total

1.  A family of mathematical models to describe the risk of infection by a sexually transmitted agent.

Authors:  R Allard
Journal:  Epidemiology       Date:  1990-01       Impact factor: 4.822

2.  The conditional latency distribution of AIDS for persons infected by blood transfusion.

Authors:  S W Lagakos; V De Gruttola
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

Review 3.  Mathematical and statistical studies of the epidemiology of HIV.

Authors:  R M Anderson
Journal:  AIDS       Date:  1989-06       Impact factor: 4.177

4.  Transmission dynamics of HIV infection.

Authors:  R M May; R M Anderson
Journal:  Nature       Date:  1987 Mar 12-18       Impact factor: 49.962

5.  The Markov process in medical prognosis.

Authors:  J R Beck; S G Pauker
Journal:  Med Decis Making       Date:  1983       Impact factor: 2.583

6.  Needles that kill: modeling human immunodeficiency virus transmission via shared drug injection equipment in shooting galleries.

Authors:  E H Kaplan
Journal:  Rev Infect Dis       Date:  1989 Mar-Apr

7.  Improved short-term survival of AIDS patients initially diagnosed with Pneumocystis carinii pneumonia, 1984 through 1987.

Authors:  J E Harris
Journal:  JAMA       Date:  1990-01-19       Impact factor: 56.272

8.  A larger spectrum of severe HIV-1--related disease in intravenous drug users in New York City.

Authors:  R L Stoneburner; D C Des Jarlais; D Benezra; L Gorelkin; J L Sotheran; S R Friedman; S Schultz; M Marmor; D Mildvan; R Maslansky
Journal:  Science       Date:  1988-11-11       Impact factor: 47.728

9.  Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco.

Authors:  R E Chaisson; A R Moss; R Onishi; D Osmond; J R Carlson
Journal:  Am J Public Health       Date:  1987-02       Impact factor: 9.308

10.  Risk factors for human immunodeficiency virus infection in intravenous drug users.

Authors:  E E Schoenbaum; D Hartel; P A Selwyn; R S Klein; K Davenny; M Rogers; C Feiner; G Friedland
Journal:  N Engl J Med       Date:  1989-09-28       Impact factor: 91.245

View more
  8 in total

Review 1.  AIDS policy modeling for the 21st century: an overview of key issues.

Authors:  M S Rauner; M L Brandeau
Journal:  Health Care Manag Sci       Date:  2001-09

2.  Using simulation for AIDS policy modeling: benefits for HIV/AIDS prevention policy makers in Vienna, Austria.

Authors:  Marion S Rauner
Journal:  Health Care Manag Sci       Date:  2002-04

3.  Strategies to prevent HIV infection in the United States.

Authors:  A R Hinman
Journal:  Am J Public Health       Date:  1991-12       Impact factor: 9.308

4.  The cost-effectiveness of HIV prevention targeting: how much more bang for the buck?

Authors:  J G Kahn
Journal:  Am J Public Health       Date:  1996-12       Impact factor: 9.308

5.  The cost-effectiveness of Vancouver's supervised injection facility.

Authors:  Ahmed M Bayoumi; Gregory S Zaric
Journal:  CMAJ       Date:  2008-11-18       Impact factor: 8.262

Review 6.  Young Drug Users: a Vulnerable Population and an Underutilized Resource in HIV/HCV Prevention.

Authors:  Pedro Mateu-Gelabert; H Guarino; K Quinn; P Meylakhs; S Campos; A Meylakhs; D Berbesi; D Toro-Tobón; E Goodbody; D C Ompad; S R Friedman
Journal:  Curr HIV/AIDS Rep       Date:  2018-08       Impact factor: 5.071

7.  Needle and syringe programs in Yunnan, China yield health and financial return.

Authors:  Lei Zhang; Lorraine Yap; Zhuang Xun; Zunyou Wu; David P Wilson
Journal:  BMC Public Health       Date:  2011-04-21       Impact factor: 3.295

8.  HIV incidence among people who inject drugs in the Middle East and North Africa: mathematical modelling analysis.

Authors:  Ghina R Mumtaz; Susanne F Awad; Ali Feizzadeh; Helen A Weiss; Laith J Abu-Raddad
Journal:  J Int AIDS Soc       Date:  2018-03       Impact factor: 5.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.